Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Secretary of Agriculture Brooke Rollins on Wednesday announced a plan to enhance the agency's ability to detect, control and ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Option chain shows key data for Verve Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market ...

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

Global shares are mostly higher and oil prices have slipped as investors await a decision on interest rates by the Federal Reserve. The inflation-fighters at the Fed are expected to ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...